Memorial Sloan Kettering Cancer Center

- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
- Conditions
- Breast Cancer
- Interventions
- Radiation: Intra Operative Radiation Therapy (IORT)
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00595062
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
- Conditions
- CNS LymphomaCNS Brain CancerNon-Hodgkin's Lymphoma
- Interventions
- Other: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00596154
- Locations
- πΊπΈ
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈMemorial Sloan Kettering Commack, Commack, New York, United States
Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma
- Conditions
- Cervical CancerEndometrial CancerCervical Carcinoma
- Interventions
- Other: Lymphatic Mapping
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 151
- Registration Number
- NCT00595725
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00596219
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00594815
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
- Conditions
- Brain TumorCns CancerBrain CancerCognitive Dysfunction
- Interventions
- Other: donepezil and questionaires
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00594633
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
- Conditions
- Primary Brain TumorBrain CancerRecurrent Malignant Gliomas
- Interventions
- Other: bevacizumab and radiation (IMRT)
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00595322
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
- Conditions
- PediatricHodgkin's Disease
- Interventions
- Drug: COPP/ABVDrug: intensive chemo with concurrent growth factor
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00592111
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Model for Genetic Susceptibility: Melanoma
- Conditions
- MelanomaSkin Cancer
- Interventions
- Behavioral: Questionnaire
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4082
- Registration Number
- NCT00591500
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers
- Conditions
- Smoking Cessation
- Interventions
- Behavioral: Standard Care onlyBehavioral: Dental Hygienist provided counseling with personalized risk communication + Brief QuestionnaireBehavioral: Dental Hygienist provided counseling + Brief Questionnaire
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1072
- Registration Number
- NCT00591175
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States